# Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

> **NCT00299819** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 45 (actual)

## Conditions studied

- Lupus

## Interventions

- **BIOLOGICAL:** MEDI-545
- **BIOLOGICAL:** MEDI 545
- **BIOLOGICAL:** MEDI-545
- **BIOLOGICAL:** MEDI-545
- **BIOLOGICAL:** MEDI-545

## Key facts

- **NCT ID:** NCT00299819
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2007-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299819, "Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00299819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*